Microbix expects full-year 2026 results in line with guidance in its current MD&A
Company is pursuing new client programs and aims to drive sales growth across all business lines
Microbix aims to improve gross margins and deliver bottom-line results
Overview
Canada life sciences manufacturer's fiscal Q3 revenue rose 17% yr/yr
Company's net loss narrowed from prior year as gross margin improved to 54%
Growth driven by higher antigen and QAPs sales to new and existing customers
Result drivers
Antigen sales - Q3 antigen revenue rose 20% yr/yr, mainly due to sales to a key customer increasing by over 40%
QAPs sales - QAPs revenue grew 13% yr/yr, primarily from new customers for PTDx category products
Improved margins - Gross margin rose to 54% from 41% last yr, as increased antigen and QAPs sales covered more fixed manufacturing costs and manufacturing-related operating expenses declined
MLAB•
